Introduction — A Question of Practice and Numbers
How often does compliance look good on paper but falter at the bench? I ask because I once sat through a midnight review where a single deviation revealed systemic issues across workflows. In a chemistry testing laboratory that supports sterile medical products, those deviations are not theoretical — they translate into delayed approvals and strained relationships with regulators. (I still remember the July 2019 inspection in Cambridge that changed how I run sample chains.)
Data matter: on one audit I was involved with, non-conformances tied to poor sample handling rose by nearly a quarter year-on-year, and that spike cost a small firm an extra four months to clear a submission. I write from over 15 years advising labs and running day-to-day operations, so I have a practical stake in these problems. What follows is a problem-driven take on why routine lab activity so often undermines larger compliance goals — and what to do about it next.
Where Standard Approaches Fail: The Hidden Flaws in leachables testing
Why do failures persist?
Directly: many labs treat leachables testing as an add-on rather than a core design requirement. I have seen this in workflows that rely on single-method screens (GC-MS or LC-MS alone) without robust extractables data to frame them. Chromatographic separation, mass spectrometry, and sample preparation are all necessary components, but they must be integrated, not bolted on. In November 2020 at our Manchester site, we discovered that a reliance on nominal limits of detection — without method verification against real extracts — produced false negatives. The result: a regulatory filing delayed by four months and direct costs approaching £60,000.
The traditional solution flaws are consistent: inadequate method transfer, poor matrix-matching, and insufficient emphasis on system suitability. We saw operators trusting vendor default parameters on an Agilent 6460 LC-MS, and a procurement decision to standardise on a Shimadzu GC-2010 for volatility screens without mapping method capability to the polymer extracts used in packaging studies. Those are concrete missteps. They stem from a narrow focus on throughput metrics — faster run times, shorter sample prep — which obscure the fact that subtle contaminants require method depth and cross-checks. I tell my lab teams sharply: tighten the SOPs — not as a slogan, as a practice. — I paused there deliberately.
Forward View: Practical Steps and Metrics for Selecting Better Lab Solutions
What’s Next — Principles and Practical Choices
Looking forward, there are two productive approaches: apply new technology principles to improve sensitivity and robustness, or examine concrete case examples to change practice. For most of the clients I advise (regulatory affairs leads in medtech and pharma), the pragmatic route is a hybrid: invest in better analytical workflows while documenting the change for medical device registration services and auditors. I prefer semi-formal, actionable plans — not abstract commitments. For instance, swapping to a high-resolution QTOF for untargeted screens and pairing it with orthogonal chromatographic methods reduced repeat testing in one program we ran in 2022 by 35% (measured over six months).
Case example: a mid-sized medical device client in Bristol replaced a single-method approach with a tiered strategy — targeted LC-MS/MS for known leachables, LC-QTOF for unknowns, and a standardised extractables protocol using methanol:water mixes. That change cut investigative holds and produced cleaner dossiers for their notified body review in March 2023. The lesson is not to buy kit and hope; it is to define performance targets (LOD, specificity, method ruggedness) and test them against real samples.
To choose solutions, evaluate using three clear metrics: 1) Analytical fit — does the method detect relevant chemistry at the expected limits of detection in your matrix? 2) Transferability — can SOPs and system suitability pass to another lab or auditor without bespoke tuning? 3) Total operational impact — measured by reduction in repeat tests and regulatory holds over a six- to twelve-month window. I recommend concrete targets for each metric, and to track them monthly. I have used these metrics across contracts since 2017 and they consistently reveal where nominal solutions fail. Remember — implementation matters as much as instruments. Final note: if you want a partner who understands both method science and dossier needs, consider experienced providers like Wuxi AppTec Medical device testing.
